Skip to main content

Table 3 Hazard ratios and 95% confidence intervals of the duration of hormone therapy on the diagnosis of dementia

From: Hormone therapy and the decreased risk of dementia in women with depression: a population-based cohort study

  All dementia Alzheimer’s disease Vascular dementia
Crude Adjusteda Crude Adjusteda Crude Adjusteda
Hazard ratio (95% confidence interval)
Duration of OC use (years)
 Never 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
 < 1 0.71 (0.68, 0.74) 0.92 (0.88, 0.96) 0.71 (0.67, 0.74) 0.92 (0.88, 0.97) 0.76 (0.66, 0.87) 0.96 (0.84, 1.10)
 ≥ 1 0.78 (0.74, 0.82) 0.90 (0.86, 0.95) 0.77 (0.73, 0.81) 0.89 (0.84, 0.94) 0.87 (0.75, 1.01) 0.97 (0.84, 1.13)
Duration of HRT (years)
 Never 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
 < 2 0.43 (0.41, 0.45) 0.84 (0.80, 0.88) 0.43 (0.40, 0.45) 0.84 (0.79, 0.89) 0.44 (0.38, 0.51) 0.82 (0.71, 0.96)
 2–5 0.40 (0.37, 0.43) 0.80 (0.74, 0.86) 0.39 (0.36, 0.43) 0.80 (0.74, 0.88) 0.42 (0.33, 0.53) 0.81 (0.64, 1.02)
 ≥ 5 0.48 (0.45, 0.52) 0.78 (0.72, 0.84) 0.48 (0.44, 0.52) 0.78 (0.71, 0.85) 0.39 (0.30, 0.51) 0.61 (0.47, 0.79)
  1. Abbreviations: OC oral contraceptives, HRT hormone replacement therapy
  2. aAdjusted for age, body mass index, level of income, current smoking, drinking status, regular exercise, diabetes mellitus, hypertension, and dyslipidemia